
Ocular Therapeutix (NASDAQ:OCUL) brought in sales totaling $13.19 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 225.77%, resulting in a loss of $12.54 million. Ocular Therapeutix collected $12.31 million in revenue during Q4, but reported earnings showed a $3.85 million loss.